Catalent Stock News

Beyond the catchy biotech names splashed across the headlines, experts say medical stocks in the background, like Catalent and PerkinElmer, are maybe more likely to strike it rich. Investor's Business

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments ac

We believe that Catalent stock, a global solutions provider for drugs, biologics, gene therapies, and consumer healthcare products, currently is an attractive pick over West Pharmaceutical Services, b

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.

TFF Pharmaceuticals is on the hunt for new partners, and a recently-announced agreement with Catalent could help them land just that. The two companies announced a collaboration focused on the generation, testing and manufacture of dry powder formulations Tuesday. Thin film freezing is a platform technology that works on both

TFF Pharmaceuticals (TFFP) and Catalent (CTLT) are collaborating on the testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of…

It takes guts to catch a falling knife, but sometimes the reward is worth the risk.

WASHINGTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- The Global Hydroxychloroquine Market size is expected to reach over USD 2,598.6 Million by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 5.7% during the forecast period. Market Synopsis The Hydroxychloroquine Market globally is driven majorly by high prevalence of such situations, especially in the emerging nations of Southeast Asia and Africa. Additionally, it has seen a sudden boost in demand, due to some of the restricted-scale studies which proved its efficacy opposite to COVID-19 virus. Nonetheless, a lot more clinical trials and tests are required before Hydroxychloroquine commercializes as the drug for COVID-19 treatment, states Vantage Market Research, in a report, titled "Hydroxychloroquine Market by Application (Coronavirus Disease (COVID-19), Malaria, Lupus Erythematosus, Rheumatoid Arthritis), by Distribution Channel (Online Pharmacy, Hospital Pharmacy, Retail Pharmacy), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.

Catalent, Inc. (CTLT) CEO John Chiminski on Q2 2022 Results - Earnings Call Transcript